PARP1 and cancer: Concomitant inhibition of ataxia telangiectasia and Rad3‐related protein (ATR) and poly ADP‐ribose Polymerase (PARP) pathways is a promising strategy in cancer therapy, potentially expanding the clinical utility of ATR inhibitor (ATRi) and PARP inhibitor (PARPi).